| Compds. Properties | Maraviroc | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Human Intestinal Absorption a | + | + | − | + | + | + | + | + |
| Blood Brain Barrier b | + | + | − | + | + | + | − | − |
| Renal organic cation transporter c | − | − | − | − | − | − | − | − |
| CYP450 1A2 inhibitor c | − | − | − | − | − | − | − | − |
| CYP450 2C9 inhibitor c | + | − | − | + | + | − | + | + |
| CYP450 2D6 inhibitor c | − | − | − | − | − | − | − | − |
| CYP450 2C19 inhibitor c | + | − | − | + | − | − | − | − |
| CYP450 3A4 inhibitor c | + | − | − | − | − | + | − | − |
| CYP450 inhibitory promiscuity | high | low | low | high | high | low | high | high |
| hERG inhibition I c | − | − | − | − | − | − | − | − |
| hERG inhibition II c | + | − | − | + | + | + | + | + |
| Ames test d | − | − | − | + | + | − | − | − |
| Carcinogenicity e | − | − | − | − | − | − | − | − |
| Aqueous solubility (Log S) | −3.7479 | −3.8727 | −2.4736 | −3.9044 | −3.7491 | −3.3937 | −4.3616 | −4.1589 |